ArticleFrontiers in oncology2026
Metastatic progression and treatment challenges in EBV-associated pulmonary lymphoepithelioma-like carcinoma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the clinical characteristics, treatment course, and management challenges of advanced pulmonary lymphoepithelioma-like carcinoma (LELC), with a focus on metastatic disease and treatment-interfering complications. Methods: We report the clinical course of a 42-year-old woman with EBV-associated pulmonary LELC. The patient was initially diagnosed with stage IIIB disease and underwent radical surgery followed by adjuvant chemoradiotherapy. No definite local recurrence was observed postoperatively; however, cervical lymph node metastasis developed shortly thereafter, followed by rapid progression to stage IV disease characterized predominantly by liver metastases. First-line treatment with pembrolizumab combined with chemotherapy achieved an initial partial response. During subsequent disease progression, the patient developed persistent high-grade fever refractory to antimicrobial therapy, which significantly compromised treatment continuity. Results: This case demonstrates the potentially aggressive and heterogeneous clinical behavior of pulmonary LELC despite multimodal therapy. Serial plasma EBV-DNA levels closely paralleled disease activity, decreasing during treatment response and increasing during progression. Persistent high-grade fever posed a major diagnostic and therapeutic challenge. Tumor-related fever was considered the most likely etiology, although occult infection could not be definitively excluded. Due to sustained fever, declining performance status, limited clinical experience with immunotherapy at that time, and concerns regarding treatment-related risks, immunotherapy was interrupted during the febrile period. Conclusion: Advanced pulmonary LELC may exhibit aggressive clinical behavior with predominant metastatic burden. Immunochemotherapy may provide meaningful but often transient benefit in patients with high PD-L1 expression, while dynamic plasma EBV-DNA monitoring may serve as a useful indicator of disease activity. In addition, atypical tumor-related fever may substantially interfere with treatment continuity and clinical decision-making. Early recognition and proactive management of such complications may help optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.